Relevant Updates to the Interim Bulk Drug Substances List for 503A Pharmacies 2,4,5,6 For a full list of updates, please download the complete Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act document linked above
For type 2 diabetes, GLP-1 medications are typically long-term treatments due to the progressive nature of the condition, though some patients may reduce therapy with sustained lifestyle changes
These injections can either be administered by a medical professional or be self-administered and will start on a very low dosage, slowly increasing in amount each month before reaching the target dose to ensure no severe reaction to the medication occurs
Imodium (Loperamide) uses There is one FDA-approved use for Imodium, but physicians may also use it off-label to treat other conditions
Second, as a single-center study with limited omics sample size, future validation in larger cohorts is warranted to confirm ITIH3 and ACAT1 as biomarkers
Important Note: Zepbound is not FDA-approved for diabetes management
